公开(公告)号：US11034696B2

公开(公告)日：2021-06-15

申请号：US16480762

申请日：2018-01-23

申请人： GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED

发明人： Feng Ren ,  Yingxia Sang ,  Weiqiang Xing ,  Yang Zhan ,  Baowei Zhao

IPC分类号： C07D487/04 ,  C07D407/14 ,  C07D413/14 ,  C07D487/10 ,  C07D491/048 ,  C07D498/04 ,  C07D498/10 ,  A61P25/16 ,  A61P25/28 ,  A61P25/14

摘要： Compounds of Formula (I) or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising these compounds, the use of these compounds and compositions in the treatment of diseases in which LRRK-2 kinase is involved.

公开(公告)号：US20210169862A1

公开(公告)日：2021-06-10

申请号：US17125190

申请日：2020-12-17

申请人： Neurocrine Biosciences, Inc.

发明人： Christopher F. O`Brien ,  Haig P. Bozigian

IPC分类号： A61K31/4375 ,  A61K31/4745 ,  A61P25/14 ,  A61K9/00 ,  A61K9/48 ,  A61K31/4525 ,  A61K31/4709

摘要： Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-α-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof to a patient in need thereof wherein the patient is being treated with a strong cytochrome P450 3A4 (CYP3A4) inducer.

公开(公告)号：US11026931B2

公开(公告)日：2021-06-08

申请号：US16983334

申请日：2020-08-03

申请人： Neurocrine Biosciences, Inc.

发明人： Grace S. Liang ,  Christopher F. O'Brien ,  Dao Tuyet Thai-Cuarto

IPC分类号： A61K31/4375 ,  A61P25/14 ,  A61P25/28 ,  A61P25/22 ,  A61P25/18 ,  A61P25/24 ,  A61K9/00 ,  A61K9/20 ,  A61K9/48

摘要： Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof.

公开(公告)号：US11008388B2

公开(公告)日：2021-05-18

申请号：US16358657

申请日：2019-03-19

申请人： MITSUBISHI TANABE PHARMA CORPORATION ,  OSAKA UNIVERSITY ,  NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY

发明人： Motonori Hashimoto ,  Toshihide Yamashita

IPC分类号： A61K39/395 ,  C07K16/28 ,  C12N5/10 ,  C12N15/09 ,  A61P37/00 ,  A61P25/28 ,  A61P25/02 ,  A61P25/00 ,  C07K16/22 ,  C07K16/46 ,  A61P25/14 ,  A61P27/02 ,  A61P17/06 ,  A61P27/06 ,  A61P7/04 ,  A61P11/06 ,  A61P17/00 ,  A61P19/02 ,  A61P25/18 ,  A61P1/00 ,  A61P25/16 ,  A61K39/00

摘要： The present invention aims to obtain an anti-repulsive guidance molecule a (RGMa) antibody having a high binding activity and few side effects which can be used as a medicine for preventing, treating, or preventing the relapse of neurological or immunological diseases. The problem is solved by providing an isolated RGMa binding protein which does not inhibit binding between RGMa and neogenin but neutralizes the neurite outgrowth inhibiting activity of RGMa, preferably by providing an anti-RGMa antibody which has complementarity determining regions having amino acid sequences of SEQ ID NOS: 30-35 or SEQ ID NOS: 36-40 in Sequence Listing, and SFG.

公开(公告)号：US10987370B2

公开(公告)日：2021-04-27

申请号：US14652368

申请日：2013-12-24

申请人： Ramot at Tel-Aviv University, Ltd.

发明人： Rina Rosin-Arbesfeld ,  Michal Caspi ,  Dalia Megiddo

IPC分类号： A61K31/7048 ,  A61K31/7052 ,  A61P25/28 ,  A61P25/00 ,  A61P25/14 ,  G01N33/53 ,  G01N33/567 ,  A61K49/00 ,  A61P21/00 ,  G01N33/50

摘要： Disclosed is treatment of genetic neurodegenerative or neurodevelopmental diseases that are caused by or associated with nonsense mutations or premature termination codons using macrolides. Further disclosed are methods for identifying agents that induce read-through of nonsense mutations and premature termination codons and uses thereof.

公开(公告)号：US20210100823A1

公开(公告)日：2021-04-08

申请号：US16960932

申请日：2019-04-23

申请人： Sheau-Long LEE

发明人： Sheau-Long LEE ,  Kuo-Feng HUA ,  Yu-Chieh LEE

IPC分类号： A61K31/704 ,  A61P25/14

摘要： Use of ginsenoside M1 for manufacturing a medicament for treating Huntington's disease (HD) in a subject in need; and a pharmaceutical composition for use in treating HD comprising ginsenoside M1 and a pharmaceutically acceptable carrier.

公开(公告)号：US10960076B2

公开(公告)日：2021-03-30

申请号：US15879345

申请日：2018-01-24

申请人： Church & Dwight Co. Inc.

发明人： Luis C. Muniz ,  Albert Nazareth ,  Paul A. Cox ,  Robert Frank Boutin

IPC分类号： A61K47/36 ,  A61K9/06 ,  A61K31/198 ,  A61P25/28 ,  A61K47/26 ,  A61K9/68 ,  A61P25/14 ,  A61P25/16

摘要： The present disclosure describes a gummy dosage form including: an amino acid in an amount of about 20% by weight or greater; a hydrophilic bulking agent; and a hydrophilic long-chain polymer, wherein at least a portion of the hydrophilic long-chain polymer comprises low methoxyl pectin. The gummy dosage forms can further include additives such as flavorants, fiber, and pH-adjusters. The disclosure further comprises methods for preparing such gummy dosage forms, wherein a hydrophilic bulking agent, a hydrophilic long-chain polymer, and water are combined to give a mixture and heated to give a hydrocolloid system in the form of a slurry; mixing an amino acid with the slurry; and setting the resulting mixture to give the gummy dosage form.

公开(公告)号：US10941203B2

公开(公告)日：2021-03-09

申请号：US16492954

申请日：2018-03-15

申请人： TSINGHUA UNIVERSITY

发明人： Bai Lu ,  Wei Guo ,  Hongyang Yao

IPC分类号： A61K39/395 ,  A61K39/00 ,  C12P21/08 ,  G01N33/53 ,  A61K49/00 ,  A61K49/16 ,  C07K14/00 ,  A61K38/00 ,  C07K16/28 ,  A61P25/28 ,  A61K38/18 ,  A61P25/00 ,  A61P25/02 ,  A61P27/00 ,  A61P27/06 ,  A61P27/02 ,  C07K16/00 ,  C07K14/48 ,  A61P9/10 ,  C07K16/18 ,  A61P25/14 ,  A61K9/00 ,  A61K38/17 ,  C07K14/705 ,  C07K14/47 ,  A61P25/16 ,  C12N5/0793 ,  A61P21/00 ,  A61L27/38

摘要： Provided is an isolated TrkB agonist antibody that binds to an epitope contained in one of the extracellular domains of TrkB and is capable of activating TrkB, wherein the extracellular domains comprises extracellular D1, D2, D3, D4, D5 domains and juxtamembrane domain of TrkB. Methods of using the TrkB agonist antibody in treating or reducing the risk of a TrkB associated conditions in a subject, wherein said condition is selected from cell differentiation, synaptic development, neural injury repairing and/or neurite branching.

公开(公告)号：US20210061850A1

公开(公告)日：2021-03-04

申请号：US17097569

申请日：2020-11-13

申请人： Sage Therapeutics, Inc.

发明人： Gabriel Martinez Botella ,  Boyd L. Harrison ,  Albert Jean Robichaud ,  Francesco G. Salituro ,  Richard Thomas Beresis

IPC分类号： C07J43/00 ,  C07J7/00 ,  A61P25/20 ,  A61P25/18 ,  A61P25/14 ,  A61P25/08 ,  A61P25/24

摘要： Provided herein are 19-nor C3,3-disubstituted steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.

公开(公告)号：US20210052560A1

公开(公告)日：2021-02-25

申请号：US17019346

申请日：2020-09-13

申请人： PRILENIA NEUROTHERAPEUTICS LTD.

发明人： Michael Hayden ,  Michal Geva

IPC分类号： A61K31/44 ,  A61K9/48 ,  A61P25/14

摘要： This invention provides a method of maintaining functional capacity, improving functional capacity, or lessening the decline of functional capacity in a human patient comprising periodically orally administering to the patient a pharmaceutical composition comprising pridopidine such that a dose of 90 mg of pridopidine is administered to the patient per day, so as to thereby maintain functional capacity, improve functional capacity, or lessen the decline of functional capacity in the human patient.